What helps Lilly, BI's Jardiance slash CV death risk? Not blood pressure, lipid or HbA1c reductions: study
admin 11th June 2017 Uncategorised 0Boehringer Ingelheim and Eli Lilly still don’t know what’s responsible for the dramatic reduction in cardiovascular death risk that their diabetes med Jardiance (empagliflozin) posted in its outcomes trial. But they know what isn’t.
More: What helps Lilly, BI's Jardiance slash CV death risk? Not blood pressure, lipid or HbA1c reductions: study
Source: fierce